Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael S Kostapanos

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
World Journal of Experimental Medicine|July 1, 2014
High density lipoproteins and type 2 diabetes: Emerging concepts in their relationshipMichael S Kostapanos, Moses S Elisaf
British Journal of Clinical Pharmacology|December 7, 2016
Statins and mortality: the untold storyMichael S Kostapanos, Moses S Elisaf
World Journal of Cardiology|August 24, 2011
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analysesMichael S Kostapanos, Moses S Elisaf
World Journal of Hepatology|February 7, 2022
Is there a role of lipid-lowering therapies in the management of fatty liver disease?Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
European Journal of Clinical Investigation|March 14, 2013
Fenofibrate and the kidney: an overviewMichael S Kostapanos, Matilda Florentin, Moses S Elisaf
World Journal of Hepatology|September 28, 2013
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseMichael S Kostapanos, Anastazia Kei, Moses S Elisaf
World Journal of Diabetes|February 25, 2022
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatmentMatilda Florentin, Michael S Kostapanos, Athanasia K Papazafiropoulou
Expert Opinion on Pharmacotherapy|May 26, 2010
Current role of statins in the treatment of essential hypertensionMichael S Kostapanos, Haralampos J Milionis, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Expert Opinion on Pharmacotherapy|November 19, 2019
Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?Matilda Florentin, Michael S Kostapanos, Panagiotis Anagnostis, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
World Journal of Experimental Medicine|July 1, 2014
High density lipoproteins and type 2 diabetes: Emerging concepts in their relationshipMichael S Kostapanos, Moses S Elisaf
British Journal of Clinical Pharmacology|December 7, 2016
Statins and mortality: the untold storyMichael S Kostapanos, Moses S Elisaf
World Journal of Cardiology|August 24, 2011
JUPITER and satellites: Clinical implications of the JUPITER study and its secondary analysesMichael S Kostapanos, Moses S Elisaf
World Journal of Hepatology|February 7, 2022
Is there a role of lipid-lowering therapies in the management of fatty liver disease?Ismini Tzanaki, Aris P Agouridis, Michael S Kostapanos
European Journal of Clinical Investigation|March 14, 2013
Fenofibrate and the kidney: an overviewMichael S Kostapanos, Matilda Florentin, Moses S Elisaf
World Journal of Hepatology|September 28, 2013
Current role of fenofibrate in the prevention and management of non-alcoholic fatty liver diseaseMichael S Kostapanos, Anastazia Kei, Moses S Elisaf
World Journal of Diabetes|February 25, 2022
Role of dipeptidyl peptidase 4 inhibitors in the new era of antidiabetic treatmentMatilda Florentin, Michael S Kostapanos, Athanasia K Papazafiropoulou
Expert Opinion on Pharmacotherapy|May 26, 2010
Current role of statins in the treatment of essential hypertensionMichael S Kostapanos, Haralampos J Milionis, Moses S Elisaf
Drug Safety|May 3, 2014
Benefit-risk assessment of rosuvastatin in the treatment of atherosclerosis and related diseasesMichael S Kostapanos, Christos V Rizos, Moses S Elisaf
Expert Opinion on Pharmacotherapy|November 19, 2019
Recent developments in pharmacotherapy for hypertriglyceridemia: what's the current state of the art?Matilda Florentin, Michael S Kostapanos, Panagiotis Anagnostis, et al.
Pageof 5